George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Regulatory News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Midatech Pharma PLC

3 Jul 2020 07:00

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

Intracoastal Capital LLC

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Midatech Pharma Plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

18/May/20

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

YES / NO / N/A

If YES, specify which:N/A

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

 

 

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

 

 

 

 

(2) Cash-settled derivatives:

 

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

 

TOTAL:

 

 

 

 

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

Warrant to purchase ADR’s

Details, including nature of the rights concerned and relevant percentages:

238,392 Warrants with a strike price of USD$2.05 for an equivalent number of ADR’s

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

ADR’s ISIN -US59564R3021

Sale

 

238,392

$1.57USD

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

 

 

 

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

 

 

 

 

 

 

 

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

ADR’s ISIN -US59564302

Receipt of Placement of ADR’s

238,392

$1.65USD

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

 

 

none

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

 

 

none

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

6/25/20

Contact name:

Mitchell Kopin

Telephone number*:

847-562-9030

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200702005540/en/

Copyright Business Wire 2020

Date   Source Headline
9th Jun 20208:24 amRNSForm 8.3 - Midatech Pharma plc
9th Jun 20208:10 amRNSForm 8.3 - Midatech Pharma plc
8th Jun 20207:00 amRNSResearch collaboration with Dr Reddy’s
1st Jun 202011:26 amRNSForm 8.3 - Midatech
29th May 202012:24 pmRNSForm 8.3 - Midatech Pharma plc
29th May 20209:59 amRNSHolding(s) in Company
28th May 20204:22 pmRNSForm 8.3 - Midatech Pharma Plc (Amended)
28th May 20204:00 pmRNSForm 8.3 - Midatech Pharma plc
28th May 20203:51 pmRNSForm 8.3 - [Midatech Pharma Plc]
28th May 20207:00 amRNSForm 8.3 - Midatech Pharma Plc
28th May 20207:00 amRNSForm 8.3 - Midatech Pharma Plc
27th May 20205:59 pmRNSForm 8.3 - Midatech Pharma PLC
27th May 20207:00 amRNSForm 8.3 - [Midatech Pharma plc]
26th May 20209:16 amRNSForm 8.3 - Midatech Pharma PLC
22nd May 20204:02 pmRNSForm 8.3 - Midatech Pharma plc
22nd May 20209:56 amRNSRule 2.9 Announcement
21st May 20207:01 amRNSRule 2.9 Announcement
21st May 20207:00 amRNSClosing of US$3.0m Registered Direct Offering
20th May 202011:36 amRNSForm 8.5 (EPT/RI)
19th May 202011:10 amRNSCorrection: UK Placing to Raise £1.8 million
18th May 20202:43 pmRNSUK Placing to Raise £1.8 million
18th May 20202:08 pmRNSUS$3.0 Million Registered Direct Offering
18th May 20207:00 amRNSHeadline Results for the Year Ended 31 Dec 2019
13th May 202011:28 amRNSForm 8.5 (EPT/RI)
12th May 20205:17 pmRNSAmendment to Relationship Agreement
5th May 202010:54 amRNSForm 8.3 - Midatech Pharma plc
4th May 20204:41 pmRNSSecond Price Monitoring Extn
4th May 20204:35 pmRNSPrice Monitoring Extension
4th May 202011:28 amRNSForm 8.5 (EPT/RI)
4th May 20207:00 amRNSForm 8 (OPD) (Midatech Pharma plc)
1st May 202011:08 amRNSStatement regarding Price Movement
30th Apr 20204:42 pmRNSSecond Price Monitoring Extn
30th Apr 20204:36 pmRNSPrice Monitoring Extension
23rd Apr 20208:56 amEQSForm 8.3 - Link Fund Solutions Ltd: Midatech Pharma Plc Replacement
22nd Apr 20203:51 pmRNSRule 2.9 Announcement - Typo Correction
22nd Apr 202012:00 pmRNSForm 8.3 - Midatech Pharma Plc - Replacement
22nd Apr 202011:43 amEQSForm 8.3 - Link Fund Solutions Ltd: Midatech Pharma Plc
21st Apr 20203:20 pmRNSForm 8.3 - Midatech Pharma plc
20th Apr 20205:22 pmRNSRule 2.9 Announcement
20th Apr 20207:00 amRNSStrategic Review Update, Formal Sale Process
31st Mar 20207:00 amRNSStrategic Review, Update and Directorate Changes
2nd Mar 20203:48 pmRNSResult of General Meeting
2nd Mar 20207:00 amRNSMidatech Expands MTX110 DIPG Programme
13th Feb 20202:05 pmRNSSecond Price Monitoring Extn
13th Feb 20202:00 pmRNSPrice Monitoring Extension
12th Feb 20202:13 pmRNSNotice of General Meeting
8th Jan 20204:41 pmRNSSecond Price Monitoring Extn
8th Jan 20204:35 pmRNSPrice Monitoring Extension
8th Jan 20207:00 amRNSPositive Results from MTD201-102 Study
16th Dec 20197:00 amRNSReceipt of NASDAQ Notice

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.